Crotoxin is developed by Celtic Biotech Ltd.

What development phase is Crotoxin in?

Crotoxin is FDA-approved (marketed).

Last reviewed 2026-04-20 · How we verify

Crotoxin

Celtic Biotech Ltd · FDA-approved active Small molecule Quality 0/100

Crotoxin, marketed by Celtic Biotech Ltd, is a drug with a key composition patent expiring in 2028. The primary strength of Crotoxin lies in its current market presence, leveraging its established position. The primary risk is the potential increase in competition post-patent expiry in 2028.

At a glance

Generic name	Crotoxin
Also known as	CB-24
Sponsor	Celtic Biotech Ltd
Modality	Small molecule
Therapeutic area	Other
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Open Label Clinical Trial of Intravenous Crotoxin Part 3 (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Crotoxin CI brief — competitive landscape report
Crotoxin updates RSS · CI watch RSS
Celtic Biotech Ltd portfolio CI